Search

Your search keyword '"T. A. Lister"' showing total 293 results

Search Constraints

Start Over You searched for: Author "T. A. Lister" Remove constraint Author: "T. A. Lister" Topic medicine.disease Remove constraint Topic: medicine.disease
293 results on '"T. A. Lister"'

Search Results

2. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

3. EZH2 mutations are frequent and represent an early event in follicular lymphoma

4. Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors

5. Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study

6. T-cell replete fludarabine/cyclophosphamide reduced intensity allogeneic stem cell transplantation for lymphoid malignancies

7. SNP rs6457327 in the HLA region on chromosome 6p is predictive of the transformation of follicular lymphoma

8. Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment

9. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34− fraction

10. Negative immunomagnetic selection of T cells from peripheral blood of presentation AML specimens

11. Array-based DNA methylation profiling in follicular lymphoma

12. BCL2 protein expression in follicular lymphomas with t(14;18) chromosomal translocations

13. Mutation of the Wilms’ Tumor 1 Gene Is a Poor Prognostic Factor Associated With Chemotherapy Resistance in Normal Karyotype Acute Myeloid Leukemia: The United Kingdom Medical Research Council Adult Leukaemia Working Party

14. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

15. Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma at the Time of Second or Subsequent Remission: Long-Term Follow-Up

16. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma

17. Immunotherapy for Acute Myelogenous Leukemia

18. Neurotoxicity of High-Dose Cytosine Arabinoside

19. Life expectancy of young adults with follicular lymphoma

20. Number of CD4+ Cells and Location of Forkhead Box Protein P3–Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome

21. Recombinant human granulocyte macrophage colony stimulating factor following alternating non cross resistant chemotherapy in hodgkin's disease

22. Bortezomib Therapy in Patients With Relapsed or Refractory Lymphoma: Potential Correlation of In Vitro Sensitivity and Tumor Necrosis Factor Alpha Response With Clinical Activity

23. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML

24. Secondary Central Nervous System Lymphoma: Risk Factors and Prophylaxis

25. The clinical course of follicular lymphoma

26. Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin’s Lymphoma

27. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events

28. Mutations ofCEBPA in acute myeloid leukemia FAB types M1 and M2

29. The relative role of peripheral blood and bone marrow for monitoring molecular evidence of disease in follicular lymphoma by quantitative real-time polymerase chain reaction

30. JH probe real-time quantitative polymerase chain reaction assay for Bcl-2/IgH rearrangements

31. Genetic susceptibility to Hodgkin's disease and secondary neoplasias: FISH analysis reveals patients at high risk of developing secondary neoplasia

32. Frequency of leukemic initiating cells does not depend on the xenotransplantation model used

33. Treatment of Hodgkin lymphoma: a 50-year perspective

34. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma

35. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

36. A randomized controlled trial to evaluate the role of interferon as initial and maintenance therapy in patients with follicular lymphoma

37. Detection of Chromosome Abnormalities Pre–High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin’s Lymphoma

38. High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin’s Lymphoma: A Case-Matched Study From the European Bone Marrow Transplant Registry

39. Localisation of a novel region of recurrent amplification in follicular lymphoma to an ?6.8 Mb region of 13q32-33

40. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma

41. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma

42. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response

43. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997

44. The World Health Organization Classification of Neoplasms of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting – Airlie House, Virginia, November, 1997

45. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma

46. The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues

47. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

48. Tumour necrosis factor polymorphisms and susceptibility to follicular lymphoma

49. CT appearances of mucosa-associated lymphoid tissue (MALT) lymphoma

50. A Prognostic Score for Advanced Hodgkin's Disease

Catalog

Books, media, physical & digital resources